The clinical hurdles to prescribing CGM
October 31, 2014- Interviewed by Steven E. Greer, MD
The portion of total Type 1 diabetes patients who use continuous glucose monitors (CGM) are still far less than 50%. We interviewed the CEO of Dexcom, Terry Gregg, with diabetes expert Jay Skyler, MD, from Miami, to discuss the clinical hurdles to prescribing CGM.
Disclaimer: Dr. Skyler has various relationships with Dexcom.
CMS Medicare Medicaid, Diabetes, Endocrinology, Internal medicine, Medical Devices, Pediatrics, Policy, Univ Miami | apples49 | 
October 31, 2014 11:22 am
